Unexpectedly, IgBD-TRAIL only showed mild to moderate growth suppression on HT29 and LS174T tumor grafts, suggesting the need to combine IgBD-TRAIL with sensitizers to combat these CRC cells with both chemotherapeutic MDR and TRAIL-resistance. The gene discussed is TNFSF10; the disease is neoplasm.